Abby S Van Voorhees: Influence Statistics

Abby S Van Voorhees

Abby S Van Voorhees

Department of Dermatology, Eastern Virginia Medical School, Norfolk, Virginia, USA. | Eastern Virginia Medical School, Norfolk, Virginia, USA | Eastern Virginia Medical ...

Abby S Van Voorhees: Expert Impact

Concepts for which Abby S Van Voorhees has direct influence: Psoriatic arthritis , Medical board , Patients psoriasis , Corrona psoriasis registry , Pustular psoriasis , Severe psoriasis , Plaque psoriasis .

Abby S Van Voorhees: KOL impact

Concepts related to the work of other authors for which for which Abby S Van Voorhees has influence: Psoriatic arthritis , Atopic dermatitis , Patients psoriasis , Lymphoid cells , Acne vulgaris , Lupus erythematosus , Monoclonal antibodies .

KOL Resume for Abby S Van Voorhees

Year
2022

Department of Dermatology, Eastern Virginia Medical School, Norfolk, Virginia, USA.

2021

Eastern Virginia Medical School, Norfolk, Virginia, USA

2020

Eastern Virginia Medical School, Norfolk, VA, USA.

2019

Department of Dermatology, Eastern Virginia Medical School, Norfolk, VA, USA, View further author information

2018

Department of Dermatology, Eastern Virginia Medical School, Norfolk

2017

Department of Dermatology, Eastern Virginia Medical School, Norfolk, VA, USA

2016

Eastern Virginia Medical School, Norfolk, Virginia

2015

Department of Dermatology, University of Pennsylvania School of Medicine, Philadelphia

2014

Department of Dermatology University of Pennsylvania Perelman School of Medicine 14 Penn Tower, 1 Convention Avenue Philadelphia PA 19104 U.S.A

Hospital of the University of Pennsylvania, Philadelphia

2013

Departments of Dermatology (Drs Gelfand, Takeshita, and Van Voorhees and Ms Wang) and Epidemiology and Biostatistics, Center for Clinical Epidemiology and Biostatistics (Dr Gelfand), Perelman School of Medicine, University of Pennsylvania, Philadelphia

2012

Departments of Dermatology, Baylor College of Medicine, Houston, Texas (Dr Hsu), Mount Sinai School of Medicine of New York University (Dr Lebwohl), Columbia University (Dr Bagel), and New York University School of Medicine (Dr Strober), New York, New York, Oregon Health and Science University, Portland (Dr Blauvelt), University of Utah School of Medicine, Salt Lake City (Drs Callis Duffin and Krueger), University of California, Los Angeles (Dr Crowley), Wake Forest University School of Medicine, Winston-Salem, North Carolina (Dr Feldman), Stanford University School of Medicine, Stanford, California (Dr Fiorentino), University of Pennsylvania, Philadelphia (Drs Van Voorhees and Wanat), Tufts University School of Medicine, Boston, Massachusetts (Drs Gottlieb and Michelon), State University of New York at Buffalo School of Medicine and Biomedical Sciences, Buffalo (Dr Kalb), Case Western Reserve University School of Medicine, Cleveland, Ohio (Dr Korman), Johns Hopkins at Green Spring, Lutherville, Maryland (Dr Morison), Henry Ford Hospital, West Bloomfield, Michigan (Dr Stein Gold), and University of Miami, Miami, Florida (Dr Weiss)

Department of Dermatology (Ms Wan, Drs Abuabara, Van Voorhees, and Gelfand, and Mr Shin), Center for Clinical Epidemiology and Biostatistics (Drs Troxel and Gelfand), and Department of Biostatistics and Epidemiology (Drs Troxel and Gelfand and Mr Shin), University of Pennsylvania Perelman School of Medicine, Philadelphia

2011

University of Pennsylvania, Department of Dermatology, Philadelphia, Pennsylvania

2010

Department of Dermatology, University of Pennsylvania, Philadelphia, PA, U.S.A

2009

University of Pennsylvania, Philadelphia, PA

2008

University of Pennsylvania, 19104, Philadelphia, PA, USA

2007

Department of Dermatology, University of Pennsylvania Hospital, Philadelphia

2006

From the University of Pennsylvania Department of Dermatology, Philadelphia

2005

Department of Dermatology, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA

University of Texas Southwestern Medical Center, Dallas, Texas University of Pennsylvania, Philadelphia, Pennsylvania

2004

From the Department of Dermatology, University of Pennsylvania, Philadelphia, PA.

2001

From the Department of Dermatology, University of Pennsylvania (AV, CCV, VPW) and Philadelphia Veterans Affairs Hospital (VPW), Philadelphia, Pennsylvania

Prominent publications by Abby S Van Voorhees

KOL-Index: 19093 . BACKGROUND: Patients with psoriasis value rapid and complete skin clearance. No head-to-head studies have focused on early responses to interleukin (IL)-17 vs. IL-23 inhibitors. OBJECTIVES: To compare early and complete skin clearance by the IL-17A inhibitor ixekizumab vs. the IL-23p19 inhibitor guselkumab. METHODS: IXORA-R, a 24-week, randomized, double-blinded study, enrolled adults with ...
Known for Plaque Psoriasis | Ixekizumab Guselkumab | Pasi Week | Head‐to‐head Comparison
KOL-Index: 13988 . OBJECTIVE: To compare the effectiveness of biologic systemic therapy, nonbiologic systemic therapy, and phototherapy for treatment of psoriasis. DESIGN: A cross-sectional design was used. SETTING: Ten outpatient dermatology sites across the United States participating in the Dermatology Clinical Effectiveness Research Network contributed to the study. PARTICIPANTS: A total of 713 patients ...
Known for Comparative Effectiveness | Plaque Psoriasis | Patients Etanercept | Monoclonal Antibodies
KOL-Index: 12264 . BACKGROUND: Chronic immunosuppression is a known risk factor for allowing latent tuberculosis (TB) infection to transform into active TB. Immunosuppressive/immunomodulatory therapies, while highly efficacious in the treatment of psoriasis and psoriatic arthritis, may be associated with an increased rate of active TB in patients receiving some of these therapies. OBJECTIVE: Our aim was to ...
Known for Latent Infection | Patients Psoriasis | Monoclonal Antibodies | Biologic Agents
KOL-Index: 12071 . BACKGROUND: The Multinational Assessment of Psoriasis and Psoriatic Arthritis (MAPP), a population-based survey of patients, dermatologists, and rheumatologists, was conducted for better understanding of the unmet needs of psoriasis and psoriatic arthritis (PsA) patients. OBJECTIVE: To report results from US physicians and patients. METHODS: Adults were contacted by household telephone, ...
Known for Psoriatic Arthritis | Psa Patients | Dermatologists Rheumatologists | Illness Surveys
KOL-Index: 11496 . BACKGROUND: There is a significant association between psoriasis and inflammatory bowel disease (IBD). Many treatments for psoriasis and psoriatic arthritis are also used for IBD. OBJECTIVE: To assess therapeutic options for patients with psoriasis and concurrent IBD. METHODS: A systematic literature search was performed for clinical studies of biologic and systemic psoriasis medications ...
Known for Psoriatic Arthritis | Inflammatory Bowel Disease | Psoriasis Ibd | Ulcerative Colitis
KOL-Index: 11263 . OBJECTIVE: To develop an evidence-based guideline for the pharmacologic and nonpharmacologic treatment of psoriatic arthritis (PsA), as a collaboration between the American College of Rheumatology (ACR) and the National Psoriasis Foundation (NPF). METHODS: We identified critical outcomes in PsA and clinically relevant PICO (population/intervention/comparator/outcomes) questions. A ...
Known for Psoriatic Arthritis | Patients Psa | National Psoriasis | Literature Review
KOL-Index: 11079 . OBJECTIVE: To evaluate the feasibility of using [18F]-fluorodeoxyglucose positron emission tomography-computed tomography (FDG-PET/CT) to detect and quantify systemic inflammation in patients with psoriasis. DESIGN: Case series with a nested case-control study. SETTING: Referral dermatology and preventive cardiology practices. PARTICIPANTS: Six patients with psoriasis affecting more than ...
Known for Computed Tomography | Positron Emission | Patients Psoriasis | Nested Casecontrol Study
KOL-Index: 10853 . OBJECTIVE: To determine if the rate of lymphoma in patients with a history of psoriasis is different from the rate of lymphoma in patients without psoriasis. DESIGN: Cohort study. SETTING: Outpatient practices of general practitioners in the United Kingdom who contribute to the General Practice Research Database. PATIENTS: The population studied was a sample of 10% of the patients 65 years ...
Known for United Kingdom | Lymphoma Patients | Psoriasis Increased Risk | Mycosis Fungoides
KOL-Index: 10739 . BACKGROUND: Psoriasis is a chronic inflammatory disease associated with dyslipidemia, cardiovascular events, and mortality. We aimed to assess and compare the effect of treatment of moderate-to-severe psoriasis with adalimumab or phototherapy on vascular inflammation and cardiovascular biomarkers. METHODS AND RESULTS: Randomized, double-blind, trial of adalimumab, phototherapy, and placebo ...
Known for Vascular Inflammation | Phototherapy Placebo | 12 Weeks | Insulin Resistance
KOL-Index: 10555 . BACKGROUND: Many patients with psoriasis are bothered by symptoms in highly visible, pruritic areas, such as the scalp. OBJECTIVE: To evaluate the efficacy and safety of apremilast for moderate to severe scalp psoriasis. METHODS: This phase 3b, double-blind, placebo-controlled study randomized adults with moderate to severe scalp psoriasis who had inadequate response/intolerance to at ...
Known for Apremilast Patients | Scalp Psoriasis | Efficacy Safety | Primary Endpoint
KOL-Index: 10252 . Psoriasis is a common, chronic, inflammatory, multisystem disease with predominantly skin and joint manifestations affecting approximately 2% of the population. In this second of 5 sections of the guidelines of care for psoriasis, we give an overview of psoriatic arthritis including its cardinal clinical features, pathogenesis, prognosis, classification, assessment tools used to evaluate ...
Known for Psoriatic Arthritis | Monoclonal Antibodies | Guidelines Psoriasis | Biologic Agents
KOL-Index: 10214 . Importance: Psoriasis is a chronic, inflammatory skin disease and has significant associated morbidity and effect on quality of life. It is important to determine whether dietary interventions help reduce disease severity in patients with psoriatic diseases. Objective: To make evidence-based dietary recommendations for adults with psoriasis and/or psoriatic arthritis from the Medical Board ...
Known for Psoriatic Arthritis | Patients Psoriasis | Dietary Interventions | Evidence Review
KOL-Index: 10145 . Psoriasis is a common, chronic, inflammatory, multisystem disease with predominantly skin and joint manifestations affecting approximately 2% of the population. In this fifth of 6 sections of the guidelines of care for psoriasis, we discuss the use of ultraviolet (UV) light therapy for the treatment of patients with psoriasis. Treatment should be tailored to meet individual patients' ...
Known for Psoriatic Arthritis | Treatment Psoriasis | Phototherapy Photochemotherapy | Efficacy Safety
KOL-Index: 9902 . Psoriasis is a common, chronic, inflammatory, multi-system disease with predominantly skin and joint manifestations affecting approximately 2% of the population. In this third of 6 sections of the guidelines of care for psoriasis, we discuss the use of topical medications for the treatment of psoriasis. The majority of patients with psoriasis have limited disease (<5% body surface area ...
Known for Psoriatic Arthritis | Topical Therapies | Treatment Psoriasis | Combination Humans
KOL-Index: 9676 . OBJECTIVE: To provide guidance about management of psoriatic disease during the coronavirus disease 2019 (COVID-19) pandemic. STUDY DESIGN: A task force (TF) of 18 physician voting members with expertise in dermatology, rheumatology, epidemiology, infectious diseases, and critical care was convened. The TF was supplemented by nonvoting members, which included fellows and National Psoriasis ...
Known for Psoriatic Disease | Task Force Guidance | National Psoriasis | Nonvoting Members

Key People For Psoriatic Arthritis

Top KOLs in the world
#1
D Gladman Gladman
psoriatic arthritis systemic lupus erythematosus patients psa
#2
Philip J Mease
psoriatic arthritis eli lilly novartis pfizer
#3
Philip S Helliwell
psoriatic arthritis tight control axial involvement
#4
Oliver M FitzGerald
psoriatic arthritis synovial tissue patients psa
#5
Christopher T Ritchlin
psoriatic arthritis radiographic progression janssen development
#6
Paul Emery
rheumatoid arthritis ankylosing spondylitis radiographic progression

Department of Dermatology, Eastern Virginia Medical School, Norfolk, Virginia, USA. | Eastern Virginia Medical School, Norfolk, Virginia, USA | Eastern Virginia Medical School, Norfolk, VA, USA | Department of Dermatology, Eastern Virginia Medical Sc